NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

$8.67
-0.48 (-5.25%)
(As of 05/17/2024 ET)
Today's Range
$8.64
$9.28
50-Day Range
$4.74
$9.56
52-Week Range
$2.86
$11.41
Volume
162,757 shs
Average Volume
277,548 shs
Market Capitalization
$367.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Verrica Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
55.7% Upside
$13.50 Price Target
Short Interest
Bearish
14.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.54mentions of Verrica Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.62) to ($0.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.33 out of 5 stars

Medical Sector

147th out of 914 stocks

Pharmaceutical Preparations Industry

58th out of 427 stocks

VRCA stock logo

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

VRCA Stock Price History

VRCA Stock News Headlines

Verrica Pharmaceuticals (VRCA) to Release Earnings on Monday
VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc (VRCA)
See More Headlines
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
5/19/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VRCA
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.50
High Stock Price Target
$16.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+55.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-67,000,000.00
Net Margins
-905.83%
Pretax Margin
-905.83%

Debt

Sales & Book Value

Annual Sales
$8.91 million
Book Value
$0.04 per share

Miscellaneous

Free Float
24,349,000
Market Cap
$367.78 million
Optionable
Optionable
Beta
1.82
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

VRCA Stock Analysis - Frequently Asked Questions

Should I buy or sell Verrica Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings
or view top-rated stocks.

What is Verrica Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Verrica Pharmaceuticals' stock. Their VRCA share price targets range from $10.00 to $16.00. On average, they predict the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 55.7% from the stock's current price.
View analysts price targets for VRCA
or view top-rated stocks among Wall Street analysts.

How have VRCA shares performed in 2024?

Verrica Pharmaceuticals' stock was trading at $7.32 on January 1st, 2024. Since then, VRCA shares have increased by 18.4% and is now trading at $8.67.
View the best growth stocks for 2024 here
.

When is Verrica Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our VRCA earnings forecast
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its quarterly earnings data on Thursday, February, 29th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.01. The business earned $1.99 million during the quarter, compared to the consensus estimate of $1.10 million. Verrica Pharmaceuticals had a negative net margin of 905.83% and a negative trailing twelve-month return on equity of 229.26%.

What ETF holds Verrica Pharmaceuticals' stock?

Simplify Propel Opportunities ETF holds 106,661 shares of VRCA stock, representing 0.99% of its portfolio.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS).

When did Verrica Pharmaceuticals IPO?

Verrica Pharmaceuticals (VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.99%) and BNP Paribas Financial Markets (0.02%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Joe Bonaccorso, John A Stalfort III, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends
.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRCA) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners